Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079392 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8079393 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8079265 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL31133413 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8082396 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8082399 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8079263 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL9235719 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL11562598 | 0.93 | PTPN1 (0.63) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL11562595 | 0.93 | PTPN1 (0.63) | PTPN1PTGS1PDE4ASNCAPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562929-B1 | MANUFACTURE OF TOCOPHERYL ACETATE | DSM IP ASSETS BV (NL) | 2007-11-14 | — | — | EP | claimed |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | INDIANA STATE UNIVERSITY | 2006-12-28 | — | — | US | claimed |
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | GHOSH SWAPAN K (US) | 2005-07-21 | — | — | US | claimed |
| CN-117096428-A | Application of novel organic alkoxide agglomerate and solid electrolyte composition | 上海科技大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-115703697-A | Novel organic alkoxide agglomerate and preparation method and application thereof | 上海科技大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-115697956-A | Preparation method of quinone compound | 上海科技大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-113735696-B | Preparation method of quinone compound | 上海科技大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-2518040-B1 | LOW-VISCOSITY LIQUID-CRYSTAL COMPOUND | FARNEX INCORPORATED (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | FARNEX INCORPORATED (JP) | 2016-03-10 | — | — | US | disclosed |
| EP-2992910-A1 | ADHESION PREVENTING AGENT | Farnex Incorporated (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-20140194536-A1 | LOW-VISCOSITY LIQUID CRYSTAL COMPOUND | CHEMGENESIS INCORPORATED (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | INDIANA STATE UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | GHOSH SWAPAN K (US) | 2005-07-21 | — | — | US | disclosed |
| EP-0782993-B1 | Process for the preparation of d,l-alpha-tocopherol in the presence of a perfluoroalkenesulfonic acid catalyst | HOFFMANN LA ROCHE (CH) | 2003-02-26 | — | — | EP | disclosed |
| EP-0782993-A1 | Process for the preparation of d,l-alpha-tocopherol in the presence of a perfluoroalkenesulfonic acid catalyst | F. HOFFMANN-LA ROCHE AG (CH) | 1997-07-09 | — | — | EP | disclosed |
| EP-0663400-A1 | Polyisoprene compounds, salts thereof, process for the preparation thereof, and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1995-07-19 | — | — | EP | disclosed |
| US-5177102-A | POLYISOPRENE COMPOUNDS AND SALTS THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0315913-B1 | ANTISEBORRHOIC TOPICAL COMPOSITIONS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1992-06-10 | — | — | EP | disclosed |
| EP-0456124-A2 | Polyisoprene compounds, salts thereof, process for the preparation thereof, and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1991-11-13 | — | — | EP | disclosed |
| EP-0315913-A1 | Antiseborrhoic topical compositions | Henkel Kommanditgesellschaft auf Aktien (DE) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194536-A1 | LOW-VISCOSITY LIQUID CRYSTAL COMPOUND | G6PD, GK, UGCG | PTPN1 1106/4885PTGS1 2252/4885PDE4A 466/4885 |
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | CD47, TSG101, LY96 | PTPN1 475/4885PTGS1 1623/4885PDE4A 2825/4885 |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | EPCAM, ICAM1, VCAM1 | PTPN1 1953/4885PTGS1 332/4885PDE4A 3939/4885 |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | CD47, LY96, CD4 | PTPN1 317/4885PTGS1 1064/4885PDE4A 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.